prostatectomy


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

prostatectomy

[‚präs·tə′tek·tə·mē]
(medicine)
Surgical removal of all or part of the prostate.
References in periodicals archive ?
A search of PubMed and MEDLINE (1946-Present) was completed using the search terms 'robot' and 'prostatectomy' or 'simple prostatectomy.
Vorstman added, "The dangers of the robotic prostatectomy are clearly evidenced by the endless lawsuits filed against surgeons and the device manufacturer; the scores of self-reported harms listed on the FDA's own product safety system, MAUDE (Manufacturer and User Facility Device Experience) representing only about 8% of actual adverse events, as well as the warnings issued by the USPSTF (U.
There are also other options besides prostatectomy.
Approximately half of patients seek some form of treatment for incontinence following prostatectomy (7), while anywhere between 6% and 9% of men ultimately elect for surgical approaches.
During the 5-year study period, the use of both IMRT and robotic prostatectomy increased from 32% to 44% of men who had low-risk disease based on the clinical stage of their tumor, Gleason score, and prostate-specific antigen (PSA) level.
Myriad's Prolaris test is the only test on the market that has consistently demonstrated prognostic value in both pre and post prostatectomy settings," said Jerry Lanchbury Ph.
This unit has used keyhole surgery for treating other urological cancers, such as kidney cancers, for many years, and, recently, after a period of training in one of the UK's leading laparoscopic prostatectomy units in Edinburgh, now offers this operation to men with prostate cancer in South West Wales.
Prostatectomy was associated with a lower odds of bowel urgency than radiotherapy 5 years after treatment (16.
Radical prostatectomy didn't significantly reduce mortality during 10 years of follow-up.
Prior to treatment, erectile dysfunction was reported by 28%, 33%, and 47% of men in the prostatectomy, EBRT, and brachytherapy groups respectively.
Upon successful conclusion of the experimental analysis, IRIS is planning to submit a 510(k) application with the FDA seeking clearance of a prognostic claim for its NADiA(TM) ProsVue(TM) as an in-vitro diagnostic assay intended to be used in conjunction with clinical evaluation as an aid in predicting risk for prostate cancer recurrence after radical prostatectomy.
The correlation between biopsy and radical prostatectomy specimens still remains a problem, specifically and significantly the undergrading of the biopsy specimen.

Full browser ?